Vericel Corporation   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Ann Arbor MI United States (1989)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2000
NCT00158613
First Marketed Drug
2016
autologous culture chondrocytes (Carticel)
First NDA Approval
2016
autologous culture chondrocytes (Carticel)
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Vericel Corporation

Active Ingredients

Marketed Drugs (1)

autologous culture chondrocytes (Carticel) (2016 NDA)

Drugs in Phase 4 Trials (1)

autologous culture chondrocytes (Carticel) (3 trials)

Drugs in Phase 3 Trials (1)

ixmyelocel-t (6 trials)

Drugs in Phase 2 Trials (3)

allogeneic bone marrow (1 trial)

bone repair cells (1 trial)

tissue repair cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alveolar Bone Loss (Phase 2)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cartilage Diseases (Phase 3)

Fractures, Bone (Phase 2)

Fractures, Stress (Phase 3)

Fractures, Ununited (Phase 2)

Heart Failure (Phase 2)

Ischemia (Phase 3)

Osteochondritis (Phase 3)

Osteochondritis Dissecans (Phase 3)

Osteonecrosis (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Pseudarthrosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 5